Jansen J B, Lundborg P, Baak L C, Greve J, Ohman M, Stöver C, Röhss K, Lamers C B
Department of Gastroenterology, St Radboud Hosptial Nijmegen, The Netherlands.
Gut. 1988 Jan;29(1):75-80. doi: 10.1136/gut.29.1.75.
Single intravenous doses of 10, 20, 40, and 80 mg and repeated once daily intravenous doses of 10 and 20 mg omeprazole induced a powerful and long lasting inhibition of pentagastrin stimulated gastric acid secretion (PAO) in healthy male volunteers. Single intravenous doses of 10, 20, 40, and 80 mg omeprazole inhibited PAO by 30% (p less than 0.01), 45% (p less than 0.01), 61% (p less than 0.01), and 80% (p less than 0.01), respectively when measured 1.5 h after dose, and by 20% (NS), 27% (NS), 36% (p less than 0.01) and 59% (p less than 0.01), respectively when measured 24 h after dose. Six days after repeated once daily intravenous doses of 10 and 20 mg omeprazole, PAO was inhibited by 63% (p less than 0.01) and 82% (p less than 0.01), respectively when measured 1.5 h after dose, and by 32% (p less than 0.01) and 43% (p less than 0.01), respectively when measured 24 h after dose. The inhibition of PAO by 10 mg administered intravenously as a single bolus injection was comparable with the inhibition by 20 mg as a single oral dose. Repeated once daily administration of 10 mg intravenously and 20 mg orally also resulted in comparable reductions in PAO. The reduction in PAO after repeated once daily oral administration of 20 mg was comparable with the effect of a single intravenous dose of 40 mg. Terminal half lives were short, but significantly (p less than 0.05) prolonged after a single intravenous injection of 80 mg. Repeated once daily intravenous administration of 10 and 20 mg did not result in prolongation of terminal half lives. It is concluded that intravenous administration of omeprazole causes a potent and long acting inhibition of pentagastrin stimulated gastric acid secretion in man. Its potency is augmented after repeated once daily administration.
在健康男性志愿者中,单次静脉注射10毫克、20毫克、40毫克和80毫克奥美拉唑以及每日重复静脉注射10毫克和20毫克奥美拉唑,均可对五肽胃泌素刺激的胃酸分泌(PAO)产生强大且持久的抑制作用。单次静脉注射10毫克、20毫克、40毫克和80毫克奥美拉唑后1.5小时测量,PAO的抑制率分别为30%(p<0.01)、45%(p<0.01)、61%(p<0.01)和80%(p<0.01);给药后24小时测量,抑制率分别为20%(无显著性差异)、27%(无显著性差异)、36%(p<0.01)和59%(p<0.01)。每日重复静脉注射10毫克和20毫克奥美拉唑6天后,给药后1.5小时测量,PAO的抑制率分别为63%(p<0.01)和82%(p<0.01);给药后24小时测量,抑制率分别为32%(p<0.01)和43%(p<0.01)。静脉推注10毫克单次给药对PAO的抑制作用与口服20毫克单次给药相当。每日重复静脉注射10毫克和口服20毫克也可使PAO产生相当程度的降低。每日重复口服20毫克后PAO的降低程度与单次静脉注射40毫克的效果相当。终末半衰期较短,但单次静脉注射80毫克后显著延长(p<0.05)。每日重复静脉注射10毫克和20毫克并未导致终末半衰期延长。结论是,静脉注射奥美拉唑可对人体五肽胃泌素刺激的胃酸分泌产生强效且长效的抑制作用。每日重复给药后其效力增强。